FN1 and cancer: However, in the case of combined Selumetinib- and Trametinib-resistant cancers, FN1 and CD44 were down-regulated; TIMP1 and SNAI2 were down-regulated only in Selumetinib-resistant ones; while SPARC was down-regulated in the case of Trametinib-resistant cancer.